Dual targeting of cell wall precursors by teixobactin leads to cell lysis

Tomoyuki Homma, Austin S Nuxoll, Autumn Brown Gandt, Patrick Ebner, Ina Engels, Tanja Schneider, Friedrich Götz, Kim Lewis, Brian P. Conlon

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Teixobactin represents the first member of a newly discovered class of antibiotics that act through inhibition of cell wall synthesis. Teixobactin binds multiple bactoprenol-coupled cell wall precursors, inhibiting both peptidoglycan and teichoic acid synthesis. Here, we show that the impressive bactericidal activity of teixobactin is due to the synergistic inhibition of both targets, resulting in cell wall damage, delocalization of autolysins, and subsequent cell lysis. We also find that teixobactin does not bind mature peptidoglycan, further increasing its activity at high cell densities and against vancomycin-intermediate Staphylococcus aureus (VISA) isolates with thickened peptidoglycan layers. These findings add to the attractiveness of teixobactin as a potential therapeutic agent for the treatment of infection caused by antibiotic-resistant Gram-positive pathogens.

Original languageEnglish (US)
Pages (from-to)6510-6517
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number11
DOIs
StatePublished - Nov 2016

Fingerprint

Cell Wall
Peptidoglycan
N-Acetylmuramoyl-L-alanine Amidase
Teichoic Acids
Anti-Bacterial Agents
Vancomycin
Staphylococcus aureus
Cell Count
teixobactin
Infection
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Homma, T., Nuxoll, A. S., Gandt, A. B., Ebner, P., Engels, I., Schneider, T., ... Conlon, B. P. (2016). Dual targeting of cell wall precursors by teixobactin leads to cell lysis. Antimicrobial Agents and Chemotherapy, 60(11), 6510-6517. https://doi.org/10.1128/AAC.01050-16

Dual targeting of cell wall precursors by teixobactin leads to cell lysis. / Homma, Tomoyuki; Nuxoll, Austin S; Gandt, Autumn Brown; Ebner, Patrick; Engels, Ina; Schneider, Tanja; Götz, Friedrich; Lewis, Kim; Conlon, Brian P.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 11, 11.2016, p. 6510-6517.

Research output: Contribution to journalArticle

Homma, T, Nuxoll, AS, Gandt, AB, Ebner, P, Engels, I, Schneider, T, Götz, F, Lewis, K & Conlon, BP 2016, 'Dual targeting of cell wall precursors by teixobactin leads to cell lysis', Antimicrobial Agents and Chemotherapy, vol. 60, no. 11, pp. 6510-6517. https://doi.org/10.1128/AAC.01050-16
Homma, Tomoyuki ; Nuxoll, Austin S ; Gandt, Autumn Brown ; Ebner, Patrick ; Engels, Ina ; Schneider, Tanja ; Götz, Friedrich ; Lewis, Kim ; Conlon, Brian P. / Dual targeting of cell wall precursors by teixobactin leads to cell lysis. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 11. pp. 6510-6517.
@article{a7078859b4b74a01a7cb9735d727d24a,
title = "Dual targeting of cell wall precursors by teixobactin leads to cell lysis",
abstract = "Teixobactin represents the first member of a newly discovered class of antibiotics that act through inhibition of cell wall synthesis. Teixobactin binds multiple bactoprenol-coupled cell wall precursors, inhibiting both peptidoglycan and teichoic acid synthesis. Here, we show that the impressive bactericidal activity of teixobactin is due to the synergistic inhibition of both targets, resulting in cell wall damage, delocalization of autolysins, and subsequent cell lysis. We also find that teixobactin does not bind mature peptidoglycan, further increasing its activity at high cell densities and against vancomycin-intermediate Staphylococcus aureus (VISA) isolates with thickened peptidoglycan layers. These findings add to the attractiveness of teixobactin as a potential therapeutic agent for the treatment of infection caused by antibiotic-resistant Gram-positive pathogens.",
author = "Tomoyuki Homma and Nuxoll, {Austin S} and Gandt, {Autumn Brown} and Patrick Ebner and Ina Engels and Tanja Schneider and Friedrich G{\"o}tz and Kim Lewis and Conlon, {Brian P.}",
year = "2016",
month = "11",
doi = "10.1128/AAC.01050-16",
language = "English (US)",
volume = "60",
pages = "6510--6517",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Dual targeting of cell wall precursors by teixobactin leads to cell lysis

AU - Homma, Tomoyuki

AU - Nuxoll, Austin S

AU - Gandt, Autumn Brown

AU - Ebner, Patrick

AU - Engels, Ina

AU - Schneider, Tanja

AU - Götz, Friedrich

AU - Lewis, Kim

AU - Conlon, Brian P.

PY - 2016/11

Y1 - 2016/11

N2 - Teixobactin represents the first member of a newly discovered class of antibiotics that act through inhibition of cell wall synthesis. Teixobactin binds multiple bactoprenol-coupled cell wall precursors, inhibiting both peptidoglycan and teichoic acid synthesis. Here, we show that the impressive bactericidal activity of teixobactin is due to the synergistic inhibition of both targets, resulting in cell wall damage, delocalization of autolysins, and subsequent cell lysis. We also find that teixobactin does not bind mature peptidoglycan, further increasing its activity at high cell densities and against vancomycin-intermediate Staphylococcus aureus (VISA) isolates with thickened peptidoglycan layers. These findings add to the attractiveness of teixobactin as a potential therapeutic agent for the treatment of infection caused by antibiotic-resistant Gram-positive pathogens.

AB - Teixobactin represents the first member of a newly discovered class of antibiotics that act through inhibition of cell wall synthesis. Teixobactin binds multiple bactoprenol-coupled cell wall precursors, inhibiting both peptidoglycan and teichoic acid synthesis. Here, we show that the impressive bactericidal activity of teixobactin is due to the synergistic inhibition of both targets, resulting in cell wall damage, delocalization of autolysins, and subsequent cell lysis. We also find that teixobactin does not bind mature peptidoglycan, further increasing its activity at high cell densities and against vancomycin-intermediate Staphylococcus aureus (VISA) isolates with thickened peptidoglycan layers. These findings add to the attractiveness of teixobactin as a potential therapeutic agent for the treatment of infection caused by antibiotic-resistant Gram-positive pathogens.

UR - http://www.scopus.com/inward/record.url?scp=84994730625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994730625&partnerID=8YFLogxK

U2 - 10.1128/AAC.01050-16

DO - 10.1128/AAC.01050-16

M3 - Article

C2 - 27550357

AN - SCOPUS:84994730625

VL - 60

SP - 6510

EP - 6517

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -